Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB26FSU74
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,424
Award facts
- Contract value 100% obligated
- $3,424.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,424.46 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. This firm fixed-price delivery order was issued on October 21, 2025, with an ultimate completion date of November 12, 2025, and carries no set-aside designation. DMS Pharmaceutical Group Inc. is performing the work at its headquarters location in Park Ridge, Illinois.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) awarded by the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to ensure consistent pharmaceutical supply to Department of Defense military healthcare facilities worldwide. The parent IDC, valued at $499.999 billion with a completion date of December 31, 2036, establishes DMS Pharmaceutical Group as a regional prime vendor contractor authorized to supply a comprehensive range of pharmaceuticals including branded and generic prescription drugs, biologics, and medical consumables. DMS Pharmaceutical Group has demonstrated substantial federal contracting capability through numerous delivery orders issued by DLA's Medical Supply Chain division, positioning the company as a critical supplier within the federal military medical system.
Quick answers
Who was awarded contract SPE2DB26FSU74?
SPE2DB26FSU74 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 21, 2025.
How much is contract SPE2DB26FSU74 worth?
The government has obligated $3,424 on SPE2DB26FSU74.
Is contract SPE2DB26FSU74 an order under another contract?
Yes. SPE2DB26FSU74 is a delivery order under SPE2DB22D9367, an indefinite delivery contract.
Was contract SPE2DB26FSU74 competed?
The extent of competition for SPE2DB26FSU74 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award